PipelineReview. Business Intellegence Center

Antibodies

7 September 2016

Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

7 September 2016

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

7 September 2016

European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

5 September 2016

Nordic Nanovector: Lilotomab Pre-Dosing of NHL Patients before Betalutin® Therapy Lowers Haematological Toxicity with No Reduction in the Tumor Absorbed Radiation Dose

5 September 2016

Benralizumab phase III trials show positive results in severe asthma

2 September 2016

FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

1 September 2016

Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment

1 September 2016

Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

1 September 2016

Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab

1 September 2016

OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer

1 September 2016

Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy

31 August 2016

FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases

30 August 2016

OncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer

30 August 2016

Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy

29 August 2016

New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016

29 August 2016

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

27 August 2016

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

22 August 2016

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus

18 August 2016

Zymeworks Receives FDA Acceptance of IND Application for ZW25, a Novel Bi-Specific Antibody, for the Treatment of HER2-Expressing Cancers

18 August 2016

European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab)

18 August 2016

Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®)

18 August 2016

Trillium Therapeutics Receives FDA Clearance to Proceed with TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

17 August 2016

Ambrx’s Innovative Antibody Drug Conjugate (ADC) US IND Active

16 August 2016

AbGenomics Announces FDA Acceptance to Commence Phase I Clinical Trial of AbGn-107 ADC Candidate for Pancreatic, Gastric, and Colorectal Cancer Treatments

12 August 2016

Phase I Clinical Trials Underway for First MERS Treatment

10 August 2016

Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation

9 August 2016

ProMetic Completes Adult Patients’ Enrolment in Pivotal IVIG Phase 3 Clinical Trial

9 August 2016

Ablynx reports compelling topline phase IIb study results with its anti-IL-6R nanobody, vobarilizumab, in RA patients, confirming its best-in-class potential

8 August 2016

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

8 August 2016

Pfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

CD40 Agonists & CD40/L Antagonists Pipeline Review
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective
RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
Ranibizumab (Lucentis) Biosimilars Pipeline Review
Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists
Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
Nectin-4-Targeted Immunotherapy Pipeline Review
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis